查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1620783

搔癢治療藥物市場：治療方法、適應症、通路、給藥途徑分類 - 2025-2030 年全球預測

Pruritus Therapeutics Market by Therapy, Disease Indication, Distribution Channel, Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年搔癢治療藥物市場價值為56.5億美元，預計到2024年將達到59.3億美元，複合年成長率為5.42%，到2030年將達到81.7億美元。

搔癢治療市場包括旨在緩解搔癢的治療和療法，而搔癢則是各種皮膚、全身和神經系統疾病引起的常見症狀。這個市場的定義是人口老化的加劇、濕疹和乾癬等皮膚病患病率的增加以及皮膚病學的進步。人們強調，與搔癢相關的疾病負擔日益嚴重，因此需要止癢藥物，這些疾病會影響患者的生活品質並導致感染疾病和心理困擾等繼發性併發症。其用途廣泛，從局部用藥和全身治療到新型生技藥品和小分子藥物。最終用途主要出現在醫院、診所和皮膚科中心。

主要市場統計
基準年[2023] 56.5億美元
預計年份 [2024] 59.3億美元
預測年份 [2030] 81.7億美元
複合年成長率（%） 5.42%

關鍵的成長要素包括患者意識的提高、醫療保健基礎設施的改善以及藥物開發的持續創新。以患者為中心的護理模式和個人化醫療的整合正在為市場擴張開闢新的途徑。該領域的機會包括利用生物技術的進步來開發更有效且副作用更少的新治療方法。生物技術公司和學術機構之間的策略聯盟可以加速研究和產品開發。

然而，這個市場面臨複雜的藥物開發流程、監管挑戰和治療核准高成本等限制。此外，競爭格局的特徵是現有多家製藥公司的存在，這可能對新公司的進入構成障礙。

該領域的創新可能會受到瘙癢分子機制的闡明和標靶治療的開發的推動。專注於改進製劑技術以提高藥物傳輸效率和患者依從性是一個有效的研究領域。該市場高度活躍，其特點是技術快速進步，並專注於研究來解決未滿足的需求。企業應保持敏捷性，注重消費者教育，並進軍新興市場，以維持和加強其成長軌跡。

市場動態：揭示快速發展的搔癢藥物市場的關鍵市場洞察

供需的動態交互作用正在改變搔癢藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 搔癢及相關疾病的盛行率增加
    • 提高皮膚健康意識和早期診斷和治療的願望
    • 加大止癢藥物研發力度
  • 市場限制因素
    • 治療費用高且治療選擇有限
  • 市場機會
    • 搔癢治療策略的進展
    • 利用精準醫學方法開發止癢藥物
  • 市場挑戰
    • 藥品和治療方法核准的嚴格法律規範

波特五力：駕馭搔癢症藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對搔癢藥物市場的影響

外部宏觀環境因素在塑造搔癢治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解搔癢治療藥物市場的競爭狀況

對搔癢治療藥物市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV定位矩陣搔癢藥市場供應商績效評估

FPNV 定位矩陣是評估搔癢治療藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪搔癢治療藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對搔癢治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 搔癢及相關疾病增加
      • 人們對皮膚健康的認知不斷增強，以及早期診斷和治療的趨勢
      • 加大止癢藥物研發力度
    • 抑制因素
      • 治療費用高且治療選擇有限
    • 機會
      • 搔癢症治療策略的進展
      • 利用精準醫學方法開發止癢藥物
    • 任務
      • 藥品和治療方法核准的嚴格法規結構
  • 市場區隔分析
    • 治療：了解搔癢治療，從速效皮質類固醇到長期免疫抑制劑
    • 疾病適應症：透過疾病適應症和治療進展探索搔癢治療藥物市場的關鍵見解
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 搔癢治療藥物市場療法

  • 抗組織胺藥
  • Calcineurin抑制劑
  • 皮質類固醇
  • 抗促效劑
  • 免疫抑制劑
  • 局部麻醉劑

第7章搔癢治療藥物市場：依疾病適應症

  • 過敏性接觸性皮膚炎
  • 異位性皮膚炎
  • 皮膚T細胞
  • 麻疹

第8章搔癢治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章搔癢治療藥物市場：依給藥途徑

  • 口服
  • 胃腸外的
  • 話題

第10章北美和南美搔癢治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區搔癢治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的搔癢治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Galderma的nemolizumab申請已被主要國家接受，未來有望核准用於治療結節性癢疹和異位性皮膚炎
    • 新的核准強化了 Maruho 的皮膚科解決方案作為有效的瘙癢治療方法
    • FDA核准Milam Pharmaceuticals 的 LIVMARLI 治療 PFIC 相關搔癢
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Asana BioSciences, LLC
  • Astellas Pharma Inc.
  • Avior Bio Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cara Therapeutics Inc.
  • Eli Lilly and Company
  • EPI Health LLC by Novan, Inc.
  • Escient Pharmaceuticals by Incyte Corporation
  • Evelo Biosciences, Inc.
  • Galderma SA
  • GlaxoSmithKline plc
  • LEO Pharma A/S
  • Mallinckrodt plc
  • MC2 Therapeutics A/S
  • NeRRe Therapeutics Ltd
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Trevi Therapeutics, Inc
  • Vanda Pharmaceuticals Inc.
  • Viatris Inc.
Product Code: MRR-8E22B61932B7

The Pruritus Therapeutics Market was valued at USD 5.65 billion in 2023, expected to reach USD 5.93 billion in 2024, and is projected to grow at a CAGR of 5.42%, to USD 8.17 billion by 2030.

The pruritus therapeutics market encompasses treatments and therapies aimed at alleviating itchiness, which is a common symptom resulting from various dermatological, systemic, or neurological conditions. This market is defined by a growing aging population, the increasing prevalence of skin disorders like eczema and psoriasis, and advancements in dermatological science. The necessity for pruritus therapeutics is underscored by the significant and increasing burden of itch-related disorders, which affect patient quality of life and can lead to secondary complications such as infections or psychological distress. Applications range from topical and systemic treatments to emerging biologics and small molecule drugs. End-use is primarily seen in hospitals, clinics, and dermatology centers.

KEY MARKET STATISTICS
Base Year [2023] USD 5.65 billion
Estimated Year [2024] USD 5.93 billion
Forecast Year [2030] USD 8.17 billion
CAGR (%) 5.42%

Key growth factors include rising patient awareness, improved healthcare infrastructure, and ongoing innovation in drug development. The integration of patient-centric care models and personalized medicine is opening new avenues for market expansion. Opportunities in this realm involve leveraging advancements in biotechnology to develop novel treatment modalities that are both effective and have minimal side effects. Strategic collaborations between biotech firms and academic institutions can expedite research and product development.

However, this market faces limitations such as complex drug development processes, regulatory challenges, and the high cost of treatment approvals. Additionally, the competitive landscape, marked by the presence of several established pharmaceutical players, can pose a barrier to entry for new companies.

Innovation in this area can be driven by the exploration of the molecular mechanisms involved in pruritus and the development of targeted therapies. Emphasis on improving formulation techniques to enhance drug delivery efficiency and patient compliance presents a worthwhile area of research. The market is highly dynamic, characterized by rapid technological advancements and a focus on research to address unmet needs. Businesses should remain agile, focusing on consumer education and tapping into emerging markets to sustain and enhance growth trajectories.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pruritus Therapeutics Market

The Pruritus Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of pruritus and its associated disorders
    • Rising awareness about skin health and inclination towards early diagnosis & treatment
    • Rising research and development related to drugs for pruritus
  • Market Restraints
    • High cost of treatment and limited availability of treatment options
  • Market Opportunities
    • Advancements in therapeutic strategies for the treatment of pruritus
    • Utilization of precision medicine approach for the development of pruritus-targeted drugs
  • Market Challenges
    • Stringent regulatory framework for the approval of drugs and therapies

Porter's Five Forces: A Strategic Tool for Navigating the Pruritus Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pruritus Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pruritus Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pruritus Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pruritus Therapeutics Market

A detailed market share analysis in the Pruritus Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pruritus Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pruritus Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pruritus Therapeutics Market

A strategic analysis of the Pruritus Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pruritus Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Asana BioSciences, LLC, Astellas Pharma Inc., Avior Bio Inc., Bausch Health Companies Inc., Bayer AG, Cara Therapeutics Inc., Eli Lilly and Company, EPI Health LLC by Novan, Inc., Escient Pharmaceuticals by Incyte Corporation, Evelo Biosciences, Inc., Galderma S.A., GlaxoSmithKline plc, LEO Pharma A/S, Mallinckrodt plc, MC2 Therapeutics A/S, NeRRe Therapeutics Ltd, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Toray Industries, Inc., Trevi Therapeutics, Inc, Vanda Pharmaceuticals Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Pruritus Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy, market is studied across Antihistamines, Calcineurin Inhibitors, Corticosteroids, Counterirritants, Immunosuppressant, and Local Anesthetics.
  • Based on Disease Indication, market is studied across Allergic Contact Dermatitis, Atopic Dermatitis, Cutaneous T-cell, and Urticaria.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of pruritus and its associated disorders
      • 5.1.1.2. Rising awareness about skin health and inclination towards early diagnosis & treatment
      • 5.1.1.3. Rising research and development related to drugs for pruritus
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and limited availability of treatment options
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in therapeutic strategies for the treatment of pruritus
      • 5.1.3.2. Utilization of precision medicine approach for the development of pruritus-targeted drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory framework for the approval of drugs and therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy: Understanding pruritus treatments, from fast-acting corticosteroids to long-term immunosuppressants
    • 5.2.2. Disease Indication: Exploring the pruritus therapeutics market, key insights by disease indication and treatment advances
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pruritus Therapeutics Market, by Therapy

  • 6.1. Introduction
  • 6.2. Antihistamines
  • 6.3. Calcineurin Inhibitors
  • 6.4. Corticosteroids
  • 6.5. Counterirritants
  • 6.6. Immunosuppressant
  • 6.7. Local Anesthetics

7. Pruritus Therapeutics Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Allergic Contact Dermatitis
  • 7.3. Atopic Dermatitis
  • 7.4. Cutaneous T-cell
  • 7.5. Urticaria

8. Pruritus Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Pruritus Therapeutics Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral
  • 9.4. Topical

10. Americas Pruritus Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pruritus Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pruritus Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Galderma's Nemolizumab Filings Accepted in Key Nations, Anticipating Future Approval for Prurigo Nodularis and Atopic Dermatitis Treatment
    • 13.3.2. New Approval Boosts Maruho's Dermatology Solutions with Effective Pruritus Treatment
    • 13.3.3. FDA Approves Mirum Pharmaceuticals' LIVMARLI for Treating PFIC-Related Pruritus
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Asana BioSciences, LLC
  • 3. Astellas Pharma Inc.
  • 4. Avior Bio Inc.
  • 5. Bausch Health Companies Inc.
  • 6. Bayer AG
  • 7. Cara Therapeutics Inc.
  • 8. Eli Lilly and Company
  • 9. EPI Health LLC by Novan, Inc.
  • 10. Escient Pharmaceuticals by Incyte Corporation
  • 11. Evelo Biosciences, Inc.
  • 12. Galderma S.A.
  • 13. GlaxoSmithKline plc
  • 14. LEO Pharma A/S
  • 15. Mallinckrodt plc
  • 16. MC2 Therapeutics A/S
  • 17. NeRRe Therapeutics Ltd
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Regeneron Pharmaceuticals, Inc.
  • 21. Sanofi S.A.
  • 22. Teva Pharmaceutical Industries Ltd.
  • 23. Toray Industries, Inc.
  • 24. Trevi Therapeutics, Inc
  • 25. Vanda Pharmaceuticals Inc.
  • 26. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. PRURITUS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PRURITUS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PRURITUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PRURITUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PRURITUS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PRURITUS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTERIRRITANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ALLERGIC CONTACT DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CUTANEOUS T-CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY URTICARIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. PRURITUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. PRURITUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023